APX-115 (Ewha-18278) is a potent, orally active pan NADPH oxidase （Nox) inhibitor (Kis: 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2, and Nox4). APX-115 effectively prevents kidney injury.

98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

DMSO:90mg/mL (285mM)

NOX2:0.57 μM (ki), Nox4(ki):0.63 μM (ki), NOX1:ki:1.08 μM

In the mouse podocyte cell line, APX-115 (5 μM; 60 min) almost completely suppresses high glucose-induced proinflammatory and profibrotic molecule expression. In the kidney, APX-115 attenuates Nox gene upregulation and protein expression while improving inflammatory and fibrotic processes [2].

APX-115 treatment decreases the urinary excretion of albumin and plasma creatinine levels. APX-115 (oral gavage; 60 mg/kg/day; for 12 weeks) significantly improves insulin resistance in diabetic mice[1].